{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:33:22Z","timestamp":1788582802088,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40265-019-1053-4","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T14:04:00Z","timestamp":1547820240000},"page":"325-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Sarecycline: First Global Approval"],"prefix":"10.1007","volume":"79","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"issue":"5","key":"1053_CR1","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945\u2013973 e33.","journal-title":"J Am Acad Dermatol."},{"issue":"11","key":"1053_CR2","first-page":"740","volume":"95","author":"L Hauk","year":"2017","unstructured":"Hauk L. Acne vulgaris: treatment guidelines from the AAD. Am Fam Physician. 2017;95(11):740\u20131.","journal-title":"Am Fam Physician"},{"key":"1053_CR3","unstructured":"Mayo Clinic. Acne. 2017. \n                    https:\/\/www.mayoclinic.org\/\n                    \n                  . Accessed 18 Oct 2018."},{"key":"1053_CR4","unstructured":"Del Rosso JQ, Gallo RL, Thiboutot D, et al. Status report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society. Part 2: perspectives on antibiotic use and the microbiome and review of microbiologic effects of selected specific therapeutic agents commonly used by dermatologists. J Clin Aesthet Dermatol. 2016;9(5):11\u20137."},{"issue":"6","key":"1053_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/bjd.15129","volume":"175","author":"SJ Sinnott","year":"2016","unstructured":"Sinnott SJ, Bhate K, Margolis DJ, et al. Antibiotics and acne: an emerging iceberg of antibiotic resistance? Br J Dermatol. 2016;175(6):1127\u20138.","journal-title":"Br J Dermatol"},{"key":"1053_CR6","unstructured":"U.S. Food and Drug Administration. Novel drug approvals for 2018. 2018. \n                    https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugInnovation\/ucm592464.htm\n                    \n                  . Accessed 18 Oct 2018."},{"key":"1053_CR7","unstructured":"Allergan Pharmaceuticals International Limited. Seysara (Sarecycline) tablets for oral use: US prescribing information. 2018. \n                    https:\/\/www.accessdata.fda.gov\/\n                    \n                  . Accessed 18 Oct 2018."},{"key":"1053_CR8","unstructured":"Warner Chilcott. Warner Chilcott and Paratek Pharmaceuticals sign collaboration agreement for novel, narrow-spectrum agents for acne and rosacea [media release]. 9 July 2007. \n                    http:\/\/www.warnerchilcot.com\n                    \n                  ."},{"key":"1053_CR9","unstructured":"Almirall Canada. Almirall buys Allergan\u2019s US dermatology portfolio for $650 million [media release]. 3 Aug 2018. \n                    http:\/\/www.almirall.com\n                    \n                  ."},{"key":"1053_CR10","unstructured":"Almirall S.A. Almirall acquires Allergan U.S. medical dermatology portfolio [media release]. 21 Sep 2018. \n                    http:\/\/www.almirall.com\n                    \n                  ."},{"key":"1053_CR11","unstructured":"U.S. Securities and Exchange Commission. Form 10-K: Paratek Pharmaceuticals, Inc. 2016. \n                    https:\/\/www.sec.gov\/Archives\/edgar\/data\/1178711\/000156459017003144\/prtk-10k_20161231.htm\n                    \n                  . Accessed 18 Oct 2018."},{"key":"1053_CR12","unstructured":"Data on file, Allergan plc, 2018."},{"key":"1053_CR13","unstructured":"Center for Drug Evaluation and Research. Application number 209521Orig1s000. Multi-discipline review. 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/209521Orig1s000MultidisciplineR.pdf\n                    \n                  . Accessed 10 Jan 2019."},{"key":"1053_CR14","unstructured":"Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5\u00a0mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol. 2018;17(9):987\u201396."},{"key":"1053_CR15","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT02413346. 2018. \n                    https:\/\/clinicaltrials.gov\n                    \n                  . Accessed 17 Oct 2018."},{"issue":"3","key":"1053_CR16","first-page":"333","volume":"17","author":"JJ Leyden","year":"2018","unstructured":"Leyden JJ, Sniukiene V, Berk DR, et al. Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study. J Drugs Dermatol. 2018;17(3):333\u20138.","journal-title":"J Drugs Dermatol"}],"updated-by":[{"DOI":"10.1007\/s40265-019-01122-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-1053-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-1053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-1053-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,18]],"date-time":"2020-01-18T00:14:45Z","timestamp":1579306485000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-1053-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1053"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-1053-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-019-01122-z","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"18 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Sarecycline: First Global Approval, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 79, issue 3, pages 325\u2013329 Almirall, LLC., requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Almirall, LLC.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}